TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21436683
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and ketamine (MK)
Study: 21436683
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and saline (MS)
Study: 19766399
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel (Scarfade)
Study: 19766399
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheet (Epi-Derm)
Study: 19766399
Drug: Topical onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical onion extract including heparin and allantoin (Contractubex)
Study: 11429022
Drug: Preemptive ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive ganciclovir treatment for asymptomatic infection
Study: 24498368
Drug: Nordic FLOX
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy
Study: 24498368
Drug: Updated plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Updated plasma YKL‐40 levels after treatment
Study: 20739874
Drug: Marine collagen
Normalized name: marine collagen, soluble
DrugBank: Marine collagen, soluble (DB14246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine collagen peptides (MCPs) treatment
Study: 17665470
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and directed exercise
Study: 7009441
Drug: Carprofen stepwise
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen stepwise 150, 200, and 250 mg/day
Study: 7009441
Drug: Carprofen 350,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen 350, 400, and 450 mg/day
Study: 7009441
Drug: Carprofen low
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen low dosage regimen
Study: 31196016
Drug: Carglumic acid
Normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carglumic acid (50 mg/kg/day) plus standard therapy (protein-restricted diet, L-carnitine, and metronidazole)
Study: 31196016
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (protein-restricted diet, L-carnitine, and metronidazole)
Study: 21071558
Drug: EPO therapy
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO therapy (50 IU/kg/wk) for 52 weeks
Study: 21071558
Drug: No EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No EPO therapy (control group)
Study: 18536953
Drug: Alendronate 280
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 280 mg once-weekly oral buffered solution (OW OBS)
Study: 18536953
Drug: Alendronate 40
Normalized name: ALENDRONATE 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 40 mg/day tablet
Study: 11797178
Drug: Protease Inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease Inhibitor (group C)
Study: 28490349
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) intervention consisting of one 60-minute session and seven 30-minute telephone/Skype sessions over an eight-week period.
Study: 23698243
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection (0.5 mL dexamethasone suspension and 3 mL lidocaine)
Study: 23698243
Drug: Palpation-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided injection (0.5 mL dexamethasone suspension and 3 mL lidocaine)
Study: 19052293
Drug: combination (comb)
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination (comb)
Study: 14964327
Drug: Sound field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sound field FM amplification (SFA) in treatment group classrooms
Study: 10194143
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms fenoterol‐80 micrograms ipratropium bromide (four puffs) from a metered‐dose inhaler (MDI)
Study: 10194143
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg fenoterol‐500 micrograms ipratropium bromide in 5 ml saline from a nebulizer (NEB)
Study: 2181040
Drug: Various combinations
Normalized name: various combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various combinations of existing antileprosy drugs administered for 5 years to new untreated patients (Group I) and relapsed patients (Group II)
Study: 2181040
Drug: Clofazimine (even
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine (even in low doses)
Study: 31253441
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis (baseline Lp(a) ≥50 mg/dL)
Study: 21960156
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg levobupivacaine in 60 mL 0.9% saline
Study: 21960156
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL 0.9% saline (placebo)
Study: 17466722
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (30 minutes per day, 5 days a week for 4 weeks)
Study: 9787543
Drug: Antimicrobial oral
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial oral rinse (0.12 percent chlorhexidine)
Study: 19855209
Drug: Continuous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lateral rotational therapy
Study: 11737740
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose nebulized albuterol therapy (0.15 mg/kg)
Study: 11737740
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose nebulized albuterol (0.075 mg/kg) plus nebulized ipratropium bromide therapy (250 microg/dose)
Study: 9422890
Drug: Ropivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Study: 9422890
Drug: Bupivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (20 mg test dose, 30 mg main dose, 25 mg top-up)
Study: 12959320
Drug: Minaprine 100
Normalized name: minaprine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine 100 mg
Study: 2827471
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus sulindac (200 mg BID)
Study: 2827471
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus indomethacin (50 mg BID)
Study: 25015066
Drug: Late remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late remote ischemic preconditioning (L‐RIPC)
Study: 17971112
Drug: MOD preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD preparation restored with composite resin (Z‐250, 3M ESPE)
Study: 17971112
Drug: MOD preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD preparation and endodontic treatment
Study: 17971112
Drug: MOD preparation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD preparation, endodontic treatment, and composite resin restoration
Study: 17971112
Drug: MOD preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOD preparation
Study: 15957693
Drug: 9.0 mg
Normalized name: NITROGLYCERIN 9.0 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.0 mg glucose-free bupivacaine with added fentanyl 20 microg (group BF)
Study: 15957693
Drug: 11.0 mg
Normalized name: ZINC OXIDE 11.0 mg in 100 mL / TITANIUM DIOXIDE 6.2 mg in 100 mL TOPICAL LOTION [Yes To Cucumbers Daily Moisturizer SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.0 mg glucose-free bupivacaine alone (group B)
Study: 7564346
Drug: UP269-6 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP269-6 (doses ranging from 5 to 180 mg)
Study: 7564346
Drug: UP269-6 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP269-6 (20 mg and 40 mg)
Study: 1767900
Drug: Thick layer
Normalized name: Bayer Aspirin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thick layer of lignocaine-prilocaine cream (2.0 ml)
Study: 1767900
Drug: Thin layer
Normalized name: Bayer Aspirin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thin layer of lignocaine-prilocaine cream (0.5 ml)
Study: 6951009
Drug: High-calorie dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie dietary supplement providing a minimum of 50% of energy requirements
Study: 28411244
Drug: Drug-Eluting Stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stents (DESs) with paclitaxel
Study: 22433279
Drug: Aciclovir 400
Normalized name: Aciclovir 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 400 mg orally twice daily
Study: 19727537
Drug: Trospium ER
Normalized name: trospium Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium ER 60 mg once daily for 12 weeks
Study: 7875148
Drug: GM‐CSF, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF, 5 micrograms/kg daily (intravenously or subcutaneously) for ten days
Study: 23361871
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication for first 3 months, then bosentan for 6 months)
Study: 17894257
Drug: Treatment participants
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment participants received a series of mailed materials and two educational calls over 6 months.
Study: 9849179
Drug: Increased oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased oral fluid intake
Study: 7852747
Drug: corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn oil (4 capsules of 1g/day)
Study: 30240132
Drug: CSL112 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 2 g
Study: 28790038
Drug: ParticiPAte CP
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ParticiPAte CP (participation focused therapy)
Study: 22276690
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of wide-diameter implants in fresh molar extraction sockets
Study: 22276690
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of wide-diameter implants in healed sites
Study: 22276690
Drug: Immediately placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediately placed implants
Study: 22276690
Drug: Delayed placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed placed implants
Study: 21498904
Drug: Cognitive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive intervention group (IG) receiving weekly sessions of group‐based multicomponent cognitive intervention.
Study: 18574688
Drug: Three‐way combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three‐way combination of GSTP1 105AA/AG and null genotypes for both GSTM1 and GSTT1
Study: 11922398
Drug: Troxerutin 150
Normalized name: troxerutin
DrugBank: Troxerutin (DB13124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin 150 mg and carbazochrome 1.5 mg
Study: 9517631
Drug: Foscarnet 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet 90 mg/kg b.i.d. for 21 days
Study: 9517631
Drug: Ganciclovir 5
Normalized name: ganciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir 5 mg/kg b.i.d. for 21 days
Study: 8299789
Drug: CC-stimulated, hCG-timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-stimulated, hCG-timed IUI
Study: 2680583
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg protriptyline
Study: 2680583
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg protriptyline
Study: 786204
Drug: Imipramine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 300 mg daily
Study: 786204
Drug: Imipramine 150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 150 mg daily
Study: 31063575
Drug: Aclidinium (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium (400 μg twice daily)
Study: 19918595
Drug: Local antibiotics
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antibiotics (two groups with proven efficacy)
Study: 10618679
Drug: G(-6)A genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: G(-6)A genotype
Study: 24305422
Drug: Novel hydroxyphenoxy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel hydroxyphenoxy propionic acid, ellagic acid, yeast extract, and salicylic acid formulation applied twice daily
Study: 24305422
Drug: Standard prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prescription combination of 4% hydroquinone cream and 0.025% tretinoin cream applied nightly
Study: 24305422
Drug: Both products
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both products (novel formulation and prescription combination)
Study: 1544585
Drug: Low-dose antihypertensive
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antihypertensive medication (chlorthalidone)
Study: 18549463
Drug: PEG‐IFN alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2b 1.0 micro/kg/week plus RBV 8‐10 mg/kg/day for 24 weeks (group A)
Study: 15852629
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (6.17 +/- 0.98 mg x kg(‐1) x h(‐1)) after delivery
Study: 14592306
Drug: Oral interface
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral interface (Oracle)
Study: 8568290
Drug: RRV‐TV (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV‐TV (tetravalent rhesus-human rotavirus vaccine)
Study: 8568290
Drug: RRV‐S1 (monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV‐S1 (monovalent rhesus-human rotavirus vaccine)
Study: 8568290
Drug: Rotavirus vaccines
Normalized name: Rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccines (both RRV‐S1 and RRV‐TV)
Study: 1658700
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 and 1.25 mg)
Study: 7056949
Drug: RW-Cl (clustered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RW-Cl (clustered doses of ragweed extract at 3-wk intervals)
Study: 7056949
Drug: RW-Wk (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: RW-Wk (weekly injections of single doses of ragweed extract)